VGTI develops research and teaching programs to respond to infectious disease threats, including AIDS, chronic viral infection-associated diseases, newly emerging diseases, and infectious diseases of the elderly. Learn more
About us
The Vaccine and Gene Therapy Institute (VGTI) at Oregon Health & Science University (OHSU) has assembled a multidisciplinary team of scientists to respond to serious viral disease threats, including AIDS, chronic viral infection-associated diseases, newly emerging viral diseases and infectious diseases of the elderly. Our Programs are intended to span the continuum between basic and clinical science, in which discoveries are rapidly advanced from the level of molecular and cellular biology through animal models and ultimately into clinical testing. Learn more
Upcoming seminars
Thursday January 31st, 2019 9:30am
VGTI Seminar Room - West Campus
Topic: Function of the rhesus Rhadinovirus CD200 homologue and it's effects during viral infection
Speaker: Ryan Estep, Ph.D.
Assistant Staff Scientist, VGTI
Oregon Health & Science University
Thursday February 7th, 2019 9:30am
VGTI Seminar Room - West Campus
Topic: Allogeneic hematopoietic cell transplantation in Mauritian cynomolgus macaques: SIV reservoir impacts and opportunistic virus-associated complications
Speaker: Helen Wu, Ph.D.
Postdoctoral Researcher, VGTI
Oregon Health & Science University
Recent publications
PLoS Pathog, February 21, 2019
Casting a wider net: Immunosurveillance by nonclassical MHV molecules
MBio, February 12, 2019
Human Cytomegalovirus immediate early 86-kDa protein blocks transcription and
induces degradation of the immature interleukin-1β protein during
virion-mediated activation of the AIM2 inflammasome
OHSU, January 23, 2019
New vaccine offers fresh take on malaria fight
PLOS One, January 23, 2019
Cytomegalovirus vectors expressing plasmodium knowlesi antigens induce immune
responses that delay parasitemia upon sporozoite challenge
Journal of Virology, January 9, 2019
Rhesus Macaque Rhadinovirus encodes a viral interferon regulatory factor to
disrupt promyelocytic leukemia nuclear bodies and antagonize type I interferon
signaling